WJHL-TV

EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC at AACR ...

Eilean Therapeutics is a biopharmaceutical company focused on the development of best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies and ...
Nasdaq

Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis

Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trials ...
MarketWatch

EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC at AACR ...

The MarketWatch News Department was not involved in the creation of this content. DOVER, Del., Oct. 13, 2025 /PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to ...